Role of p38 mitogen-activated protein kinase in cardiac remodelling

British Journal of Pharmacology

Volumn 150, Issue 2, 2007, Pages 130-135

  Frantz, S ^a   Behr, T ^a   Hu, K ^a   Fraccarollo, D ^a   Strotmann, J ^a   Goldberg, E ^a   Ertl, G ^a   Angermann, C E ^a   Bauersachs, J ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Hypertrophy; Myocardial infarction; p38; Remodeling

Indexed keywords

4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL] CYCLOHEXANOL; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; COLLAGEN; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE P38; PLACEBO; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY LIGATION; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; ECHOCARDIOGRAPHY; EXPERIMENTAL STUDY; HEART DILATATION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEMODYNAMICS; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANIMALS; IMIDAZOLES; INFLAMMATION; MALE; MYOCARDIAL INFARCTION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIMIDINES; RATS; RATS, WISTAR; VENTRICULAR REMODELING;

EID: 33846487259     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706963     Document Type: Article

References (23)

1. Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S et al. (2001). SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J Pharmacol Exp Ther 296: 312-321.
2. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G (2001). Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104: 982-985.
3. Behr TM, Nerurkar SS, Nelson AH, Coatney RW, Woods TN, Sulpizio A et al. (2001). Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation 104: 1292-1298.
4. Braz JC, Bueno OF, Liang Q, Wilkins BJ, Dai YS, Parsons S et al. (2003). Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest 111: 1475-1486.
5. Carluccio E, Biagioli P, Alunni G, Murrone A, Giombolini C, Ragni T et al. (2006). Patients with hibernating myocardium show altered left ventricular volumes and shape, which revert after revascularization: evidence that dyssynergy might directly induce cardiac remodeling. J Am Coll Cardiol 47: 969-977.
6. Chang L, Karin M (2001). Mammalian MAP kinase signalling cascades. Nature 410: 37-40.
7. Cook SA, Sugden PH, Clerk A (1999). Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease. J Mol Cell Cardiol 31: 1429-1434.
8. Frantz S, Calvillo L, Tillmanns J, Elbing I, Dienesch C, Bischoff H et al. (2005). Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alphaglucosidase inhibitor acarbose. FASEB J 19: 591-593.
9. Frantz S, Hu K, Widder J, Bayer B, Witzel CC, Schmidt I et al. (2004). Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br J Pharmacol 141: 9-14.
10. Gao F, Yue TL, Shi DW, Christopher TA, Lopez BL, Ohlstein EH et al. (2002). p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc Res 53: 414-422.
11. Gaudron P, Hu K, Schamberger R, Budin M, Walter B, Ertl G (1997). Effect of endurance exercise training early or late after coronary artery occlusion on left ventricular remodeling, hemodynamics, and survival in rats with chronic transmural myocardial infarction. Circulation 89: 402-412.
12. Gorog DA, Tanno M, Cao X, Bellahcene M, Bassi R, Kabir AM et al. (2004). Inhibition of p38 MAPK activity fails to attenuate contractile dysfunction in a mouse model of low-flow ischemia. Cardiovasc Res 61: 123-131.
13. Hu K, Gaudron P, Anders HJ, Weidemann F, Turschner O, Nahrendorf M et al. (1998). Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin. Cardiovasc Res 39: 401-412.
14. Kaiser RA, Lyons JM, Duffy JY, Wagner CJ, McLean KM, O'Neill TP et al. (2005). Inhibition of p38 reduces myocardial infarction injury in the mouse but not pig following ischemia-reperfusion. Am J Physiol Heart Circ Physiol 289: H2747-H2751.
15. Liao P, Georgakopoulos D, Kovacs A, Zheng M, Lerner D, Pu H et al. (2001). The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci USA 98: 12283-12288.
16. Liu YH, Wang D, Rhaleb NE, Yang XP, Xu J, Sankey SS et al. (2005). Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction. J Card Fail 11: 74-81.
17. Petrich BG, Wang Y (2004). Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies. Trends Cardiovasc Med 14: 50-55.
18. Ren J, Zhang S, Kovacs A, Wang Y, Muslin AJ (2005). Role of p38alpha MAPK in cardiac apoptosis and remodeling after myocardial infarction. J Mol Cell Cardiol 38: 617-623.
19. See F, Thomas W, Way K, Tzanidis A, Kompa A, Lewis D et al. (2004). p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol 44: 1679-1689.
20. Shimizu N, Yoshiyama M, Omura T, Hanatani A, Kim S, Takeuchi K et al. (1998). Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res 38: 116-124.
21. Wang Y, Huang S, Sah VP, Ross Jr J, Brown JH, Han J et al. (1998). Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 273: 2161-2168.
22. Widder J, Behr T, Fraccarollo D, Hu K, Galuppo P, Tas P et al. (2004). Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent. Cardiovasc Res 63: 161-167.
23. Zhang S, Weinheimer C, Courtois M, Kovacs A, Zhang CE, Cheng AM et al. (2003). The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J Clin Invest 111: 833-841.